Histone Lysine Demethylase Inhibitors.
Cold Spring Harb Perspect Med
; 7(1)2017 Jan 03.
Article
em En
| MEDLINE
| ID: mdl-28049654
ABSTRACT
The dynamic regulation of covalent modifications to histones is essential for maintaining genomic integrity and cell identity and is often compromised in cancer. Aberrant expression of histone lysine demethylases has been documented in many types of blood and solid tumors, and thus demethylases represent promising therapeutic targets. Recent advances in high-throughput chemical screening, structure-based drug design, and structure-activity relationship studies have improved both the specificity and the in vivo efficacy of demethylase inhibitors. This review will briefly outline the connection between demethylases and cancer and will provide a comprehensive overview of the structure, specificity, and utility of currently available demethylase inhibitors. To date, a select group of demethylase inhibitors is being evaluated in clinical trials, and additional compounds may soon follow from the bench to the bedside.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Histonas
/
Inibidores Enzimáticos
/
Histona Desmetilases
/
Neoplasias
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article